Novartis India board to approve Q2 FY27 results on Nov 3

Board meeting set for Q2 and half-year results

Novartis India Ltd informed the BSE that its board will meet on November 3, 2026, to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026. The company also indicated that the trading window will close from October 1, 2026. The disclosure places the focus on the company’s near-term reporting calendar and compliance steps around unpublished price sensitive information.

Trading window closure and compliance timeline

The company stated that the trading window will be closed from October 1, 2026. Such closures typically align with internal processes ahead of results finalisation and board consideration. For investors tracking event risk, the November 3 meeting date sets a clear milestone for the next financial update.

Recent schedule of financial result approvals

Novartis India has previously notified the exchange about board meetings for periodic results. It informed BSE that a meeting was scheduled on May 12, 2026, to consider and approve audited financial results for the quarter and financial year ended March 31, 2026. Another board meeting was scheduled on January 28, 2026, to consider and approve unaudited financial results for the quarter ended December 31, 2025. The company also disclosed an outcome of a board meeting held on July 29, 2025, which included approval of unaudited financial statements for the quarter ended June 30, 2025.

Key corporate actions: Minipress and Minipres trademarks

Separately from the results calendar, the company’s board approved an acquisition related to the Minipress and Minipres trademarks registered in India, along with related intellectual property, from Pfizer Inc. and Pfizer Products Inc. Novartis India executed an asset purchase agreement and trademark assignment deeds on September 7, 2026. The total consideration for this acquisition was stated as ₹1,250 crore. The disclosure also stated that signing and closing were intended to occur simultaneously.

Distribution agreement termination with Dr Reddy’s

Novartis India’s board also approved termination of its exclusive distribution and promotion agreement with Dr Reddy’s Laboratories. The agreement that is being terminated was originally signed on February 11, 2022. The termination agreement was executed on August 7, 2026, and was set to take effect on September 30, 2026. After that date, Novartis India was to regain exclusivity and market access for the covered products, as stated in the disclosure.

Board decisions on control and governance matters

The company disclosed that its board, in a meeting held on July 29, 2026, approved a change in control of the company. In a later board meeting held on August 17, 2026, the board approved adoption of a new Memorandum of Association to align with Table A of Schedule I of the Companies Act, 2013. The same meeting also approved a proposal for a change of company name and a consequential alteration of the Memorandum of Association. These disclosures indicate that the company has had multiple board-led corporate actions alongside routine financial approvals.

Governance and rights disclosures noted

The available information also stated that there is no rights history available for Novartis India. It additionally listed “pillar scores” as Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A. These points were presented as part of the data accompanying the company’s disclosures.

Key events at a glance

Market impact: what investors can track

The immediate market-relevant trigger in the latest disclosure is the November 3, 2026 board meeting for Q2 and half-year FY2026-27 results, along with the October 1 trading window closure. Beyond results, the ₹1,250 crore trademarks acquisition from Pfizer and the termination of the Dr Reddy’s distribution and promotion arrangement represent material operating and commercial decisions that can reshape product control and market access, based on what the company stated. The company has also disclosed board approvals relating to change in control and governance documents, which can be important for shareholders tracking corporate structure and compliance actions.

Why these disclosures matter

Taken together, the disclosures show a company managing both reporting timelines and structural changes through the board process. The scheduled results meeting provides the next formal checkpoint for financial performance disclosure. The trademarks acquisition is a clearly quantified transaction, while the termination agreement has a defined execution date and effective date, giving the market a fixed timeline for change in distribution and exclusivity arrangements.

Conclusion

Novartis India’s next key date is the November 3, 2026 board meeting to approve unaudited results for the quarter and half-year ended September 30, 2026, with the trading window closed from October 1. In parallel, the company has disclosed board-approved actions including a ₹1,250 crore trademarks acquisition from Pfizer and the termination of an agreement with Dr Reddy’s effective September 30, 2026.